Stock 600351 YABAO PHARMACEUTICAL GROUP CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Yabao Pharmaceutical Group Co., Ltd

Equities

600351

CNE000001CM5

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-05-30 EDT 		5-day change 1st Jan Change
6.13 CNY +0.49% Intraday chart for Yabao Pharmaceutical Group Co., Ltd -2.39% -11.16%
04-25 Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-25 Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Yabao Pharma Gets Nod to Register Asthma Drug Montelukast Sodium Granules
MT
Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023.
CI
Yabao Pharmaceutical Group Co., Ltd announces an Increase in Equity Buyback.
CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023.
CI
Yabao Pharmaceutical Takes Over Rights of Traditional Chinese Medicine for 26 Million Yuan
MT
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023.
CI
Yabao Pharmaceutical Group Co., Ltd commences an Equity Buyback Plan for CNY 300 million worth of its shares, under the authorization approved on April 24, 2023.
CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Yabao Pharmaceutical Unit Submits FDA Application for Osteoarthritis Drug
MT
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Lupin to Market Pediatric Medicines in China Under New Deal with Yabao Pharmaceutical
MT
Lupin Limited and Yabao Pharmaceutical Co. Inc. Announce Strategic Partnership in China
CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600351 Stock
  4. News Yabao Pharmaceutical Group Co., Ltd
  5. Highlights